Teva Pharmaceutical Industries (TEVA) Land & Improvements (2012 - 2018)

Teva Pharmaceutical Industries (TEVA) has reported Land & Improvements for 7 consecutive years, with $351.0 million the latest figure, recorded in Q4 2018.

• Quarterly Land & Improvements fell 10.0% year-over-year to $351.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $351.0 million (down 10.0% YoY) and the FY2018 annual result came in at $351.0 million, down 10.0% from the prior year.
• Land & Improvements retreated to $351.0 million in Q4 2018 per TEVA's latest filing, from $361.0 million in the prior quarter.
• Over the last five years, Land & Improvements for TEVA reached as high as $459.0 million in Q3 2016 and fell as low as $351.0 million in Q4 2018.
• A 5-year average of $399.7 million and a median of $391.5 million in 2017 frame the typical range for Land & Improvements.
• Annual changes were most pronounced in 2016 — Land & Improvements increased 11.42% — and 2018, when it declined 20.44%.
• Year by year, Land & Improvements stood at $372.0 million in 2014, then advanced by 5.91% to $394.0 million in 2015, then rose by 11.42% to $439.0 million in 2016, then decreased by 11.16% to $390.0 million in 2017, then decreased by 10.0% to $351.0 million in 2018.
• According to Business Quant data, Land & Improvements over the past three periods registered $351.0 million, $361.0 million, and $374.0 million for Q4 2018, Q3 2018, and Q2 2018 respectively.